Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 12, 2016, Pages S42-S47

  Sterling, T R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluoroquinolone resistance; M. tuberculosis; Tuberculosis

Indexed keywords

BEDAQUILINE; CIPROFLOXACIN; CLOFAZIMINE; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PLACEBO; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTHROPATHY; ARTICLE; BACTERICIDAL ACTIVITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DYSGLYCEMIA; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEADACHE; HUMAN; INSOMNIA; LIVER TOXICITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RASH; SIDE EFFECT; TENDINITIS; TENDON RUPTURE; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; TREATMENT OUTCOME;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; HUMANS; LEVOFLOXACIN; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85031976764     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.16.0117     Document Type: Article

References (50)

1. Garcia-Rodriguez J A, Gomez Garcia A C. In vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993; 32: 797-808.
2. Clinical and Laboratory Standards Institute, The National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved Standard. NCCLS Document 2003; M24-A. Wayne, PA, USA: NCCLS, 2011.
3. Tomioka H, Sato K, Akaki T, et al. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999; 43: 3001-3004.
4. Ruiz-Serrano M J, Alcala L, Martinez L, et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacerium tuberculosis susceptible or resistant to firstline drugs. Antimicrob Agents Chemother 2000; 44: 2567-2568.
5. Rodriguez J C, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002; 20: 464-467.
6. Gillespie S H, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999; 44: 393-395.
7. Tortoli E, Dionisio D, Fabbri C. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains. J Chemother 2004; 16: 334-336.
8. Van Deun A, Maug A K, Salim M A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
9. Aung K J, Van D A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-1187.
10. Koh W J, Lee S H, Kang YA, et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2013; 188: 858-864.
11. Kang Y A, Shim T S, Koh W J, et al. Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes. Ann Am Thorac Soc 2016; 13: 364-370.
12. RESIST-TB. Research Excellence to Stop TB Resistance. Drugresistant TB Clinical Trials Progress Report. Geneva, Switzerland: Stop TB Partnership. http://www.resisttb.org/?page-id=1602 Accessed August 2016.
13. ClinicalTrials.gov. Shortening treatment by advancing novel drugs. Bethesda, MD, USA: ClinicalTrials.gov, 2016. https://clinicaltrials.gov/ct2/results?term=STAND+and+tuberculosis&Search=Search Accessed August 2016.
14. Jindani A, Dore C J, Mitchison D A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167: 1348-1354.
15. Gosling R D, Uiso L O, Sam N E, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 1342-1345.
16. Pletz M W, De Roux A, Roth A, Neumann K H, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48: 780-782.
17. Gillespie S H, Crook A M, McHugh T D, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371: 1577-1587.
18. Merle C S, Fielding K, Sow O B, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014; 371: 1588-1598.
19. Jindani A, Harrison T S, Nunn A J, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371: 1599-1608.
20. Dawson R, Diacon A H, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015; 385: 1738-1747.
21. Akkerman O W, van A R, Klinkenberg T, et al. Drug concentration in lung tissue in multidrug-resistant tuberculosis. Eur Respir J 2013; 42: 1750-1752.
22. Kempker R R, Barth A B, Vashakidze S, et al. Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2015; 59: 3149-3155.
23. Kjellsson M C, Via L E, Goh A, et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother 2012; 56: 446-457.
24. Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002; 49: 593-596.
25. Priori S G, Napolitano C, Di P E, Condorelli G. Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. J Clin Invest 2013; 123: 84-91.
26. Devasia R A, Blackman A, May C, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother 2009; 63: 1173-1178.
27. Farhat M R, Mitnick C D, Franke M F, et al. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. Int J Tuberc Lung Dis 2015; 19: 339-341.
28. Coeck N, de Jong B C, Diels M, et al. Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis. J Antimicrob Chemother 2016; 71: 1233-1240.
29. Maruri F, Sterling T R, Kaiga AW, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012; 67: 819-831.
30. w MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev 2014; 10: CD010705.
31. Eilertson B, Maruri F, Blackman A, Herrera M, Samuels D C, Sterling T R. High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2014; 58: 3270-3275.
32. Thee S, Garcia-Prats A J, Draper H R, et al. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Clin Infect Dis 2015; 60: 549-556.
33. Farhat M R, Jacobson K R, Franke M F, et al. Gyrase mutations are associated with variable levels of fluoroquinolone resistance in Mycobacterium tuberculosis. J Clin Microbiol 2016; 54: 727-733.
34. Rigouts L, Coeck N, Gumusboga M et al. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J Antimicrob Chemother 2016; 71: 314-323.
35. Chien J Y, Chiu W Y, Chien S T, Chiang C J, Yu C J, Hsueh P R. Mutations in gyrA and gyrB among fluoroquinolone- and multidrug-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2016; 60: 2090-2096.
36. Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis 2014; 18: 912-918.
37. Mase S R, Jereb J A, Gonzalez D, et al. Pharmacokinetics and dosing of levofloxacin in children treated for active or latent multidrug-resistant tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. Pediatr Infect Dis J 2016; 35: 414-421.
38. Adler-Shohet F C, Low J, Carson M, Girma H, Singh J. Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis. Pediatr Infect Dis J 2014; 33: 664-666.
39. Seddon J A, Hesseling A C, Finlayson H, et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis 2013; 57: 1676-1684.
40. AIDS Clinical Trials Group, International Maternal Pediatric Adolescent AIDS Clinical Trials, PHOENIx MDR-TB A5300B / P2003B. Bethesda, MD, USA: ACTG, 2016. https://actgnetwork.org/newsletter/oct2015/phoenix Accessed August 2016.
41. Yew W W, Chan C K, Chau C H, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117: 744-751.
42. Yew W W, Chan C K, Leung C C, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124: 1476-1481.
43. Aldred K J, Blower T R, Kerns R J, Berger J M, Osheroff N. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: enhancing drug activity against wild-type and resistant gyrase. Proc Natl Acad Sci USA 2016; 113: E839-E846.
44. Balcells M E, Thomas S L, Godfrey-Faussett P, Grant A D. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12: 744-751.
45. van Halsema C L, Fielding K L, Chihota V N, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS 2010; 24: 1051-1055.
46. Fillion A, Aubry A, Brossier F, Chauffour A, Jarlier V, Veziris N. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrob Agents Chemother 2013; 57: 4496-4500.
47. Chien J Y, Chien S T, Chiu W Y, Yu C J, Hsueh P R. Moxifloxacin improves treatment outcomes in patients with ofloxacin-resistant multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2016; 60: 4708-4716.
48. Tagliani E, Cabibbe A M, Miotto P, et al. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. J Clin Microbiol 2015; 53: 2961-2969.
49. Brossier F, Guindo D, Pham A, et al. Performance of the new version (v2.0) of the GenoType MTBDRsl test for detection of resistance to second-line drugs in multidrug-resistant Mycobacterium tuberculosis complex strains. J Clin Microbiol 2016; 54: 1573-1580.
50. Churchyard G J, Stevens W S, Mametja L D, et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health 2015; 3: e450-e457.